HLB Life Science Co., Ltd. (KOSDAQ:067630)
South Korea
· Delayed Price · Currency is KRW 6,770.00
+150.00 (2.27%)
Apr 2, 2025, 3:30 PM KST
HLB Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 6,138 | -5,983 | -54,277 | -49,152 | -55,797 | Upgrade
|
| Depreciation & Amortization | 5,901 | 7,696 | 5,223 | 2,484 | 2,255 | Upgrade
|
| Loss (Gain) From Sale of Assets | -23.84 | 234.83 | -3,157 | -593.47 | -310.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | 24,162 | 37,553 | 14,802 | 13,786 | 22,519 | Upgrade
|
| Loss (Gain) From Sale of Investments | -61,670 | -81,336 | 20,548 | 24,871 | 19,783 | Upgrade
|
| Loss (Gain) on Equity Investments | -1,354 | 2,607 | -2,602 | -3,576 | 7,613 | Upgrade
|
| Provision & Write-off of Bad Debts | -3,233 | -91.76 | -173.85 | -292.94 | -321.69 | Upgrade
|
| Other Operating Activities | 2,923 | 23,543 | 3,135 | -2,213 | 1,338 | Upgrade
|
| Change in Accounts Receivable | -6,780 | 4,031 | 10,149 | -1,552 | 25,417 | Upgrade
|
| Change in Inventory | -421.43 | 5,300 | -2,515 | 221.34 | 5,067 | Upgrade
|
| Change in Accounts Payable | 1,508 | -4,072 | -5,610 | 4,730 | -21,178 | Upgrade
|
| Change in Other Net Operating Assets | 845.87 | 501.09 | -15,265 | -2,798 | -4,376 | Upgrade
|
| Operating Cash Flow | -32,005 | -10,016 | -29,744 | -14,084 | 2,010 | Upgrade
|
| Capital Expenditures | -27,296 | -20,618 | -10,676 | -2,421 | -8,410 | Upgrade
|
| Sale of Property, Plant & Equipment | 98.78 | 6,652 | 832.86 | 3,526 | 50.45 | Upgrade
|
| Cash Acquisitions | - | -9,029 | -43,184 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -170.68 | 326.9 | -1,044 | -46 | -12,398 | Upgrade
|
| Investment in Securities | -8,914 | 13,786 | -25,597 | 5,712 | 15,802 | Upgrade
|
| Other Investing Activities | -1,500 | 0 | 6,846 | 1,920 | 6,090 | Upgrade
|
| Investing Cash Flow | -37,781 | -8,883 | -72,643 | 8,822 | 62.23 | Upgrade
|
| Short-Term Debt Issued | 48,000 | 7,710 | 7,400 | 1,000 | - | Upgrade
|
| Long-Term Debt Issued | 77,570 | 10,870 | 98,760 | - | 3,500 | Upgrade
|
| Total Debt Issued | 125,570 | 18,580 | 106,160 | 1,000 | 3,500 | Upgrade
|
| Short-Term Debt Repaid | -49,307 | -5,000 | -4,000 | -1,000 | -868.28 | Upgrade
|
| Long-Term Debt Repaid | -77,296 | -8,256 | -1,322 | -642.24 | -4,398 | Upgrade
|
| Total Debt Repaid | -126,603 | -13,256 | -5,322 | -1,642 | -5,267 | Upgrade
|
| Net Debt Issued (Repaid) | -1,033 | 5,324 | 100,837 | -642.24 | -1,767 | Upgrade
|
| Issuance of Common Stock | 72,172 | - | 1,000 | 129.25 | 82.59 | Upgrade
|
| Repurchase of Common Stock | - | -679.97 | - | - | - | Upgrade
|
| Other Financing Activities | 34,605 | 142.28 | 259.37 | -128.1 | - | Upgrade
|
| Financing Cash Flow | 105,744 | 4,786 | 102,096 | -641.09 | -1,684 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.52 | -97.04 | 15.56 | 0.05 | -0 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -0 | - | - | - | Upgrade
|
| Net Cash Flow | 35,956 | -14,210 | -275.23 | -5,903 | 388.25 | Upgrade
|
| Free Cash Flow | -59,301 | -30,634 | -40,420 | -16,505 | -6,400 | Upgrade
|
| Free Cash Flow Margin | -58.00% | -31.26% | -40.59% | -30.85% | -6.97% | Upgrade
|
| Free Cash Flow Per Share | -521.72 | -296.95 | -400.32 | -166.14 | -64.64 | Upgrade
|
| Cash Interest Paid | 2,919 | 2,728 | 674.73 | 250.99 | 323.63 | Upgrade
|
| Cash Income Tax Paid | 7,785 | -703.65 | 1,140 | -569.35 | 213.68 | Upgrade
|
| Levered Free Cash Flow | -60,996 | -29,493 | -33,595 | -10,410 | -21,225 | Upgrade
|
| Unlevered Free Cash Flow | -50,484 | -15,961 | -27,426 | -9,625 | -19,907 | Upgrade
|
| Change in Net Working Capital | 15,769 | -12,567 | 8,460 | -1,814 | -3,658 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.